Company news

Cullinan Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results

May 15, 2022

Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl

May 11, 2022

Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting

April 26, 2022

Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences

April 4, 2022

Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients

March 27, 2022

Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022

March 16, 2022

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

March 16, 2022

Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022

March 7, 2022

Cullinan Oncology Expands Leadership Team and Board of Directors with Appointments of Jeffrey Jones, M.D., MPH, MBA to Chief Medical Officer and Anne-Marie Martin Ph.D. to Board of Directors

February 27, 2022

Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment

January 9, 2022

FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

January 3, 2022

Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients

December 15, 2021

Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients

December 12, 2021

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2021 Financial Results

November 8, 2021

Cullinan Oncology Appoints Nadim Ahmed as Chief Executive Officer

October 17, 2021

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2021 Financial Results

August 9, 2021

Cullinan Oncology Receives FDA Clearance of Investigational New Drug (IND) Application for CLN-619, a Novel MICA/B-targeted Antibody for the Treatment of Solid Tumors

June 28, 2021

Cullinan Oncology Receives Investigational New Drug (IND) Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML

June 6, 2021

Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients

June 3, 2021

Cullinan Oncology Announces Management Transition

May 20, 2021

Cullinan Oncology to Provide CLN-081 Clinical Update at ASCO 2021

May 18, 2021

Cullinan Oncology Reports First Quarter 2021 Financial Results

May 13, 2021

Cullinan Oncology Reports Full Year 2020 Financial Results and Business Highlights

March 29, 2021

Cullinan Management, Inc. Announces Business Update

February 21, 2021

Cullinan Management Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 11, 2021

Cullinan Management Announces Pricing of Upsized Initial Public Offering

January 6, 2021

← Newer news releases

Decks

The 5 newest of 18 decks. Every deck is listed under its year.